DHL Ordered to Pay €18,000 Redundancy Package to Warehouseman

DHL has been ordered to pay over €18,000 in redundancy to a warehouseman who refused a transfer to a new site requiring a 5-hour commute. The Workplace Relations Commission upheld the complaint under the Redundancy Payments Act 1967. The employee had previously worked for 15 years at a Clondalkin warehouse, which was closed and sold off, and was offered a new job at a Tesco distribution center with a lengthy commute.

H.C. Wainwright has reiterated a Buy rating and $35.00 price target on MiNK Therapeutics (NASDAQ:INKT), a biotech company with a $256 million market cap, following the publication of a notable case study in Nature’s Oncogene on July 11 [1]. The stock has surged over 820% year-to-date, with analyst targets ranging from $35 to $70.

The case study details a 49-year-old male patient with germ cell neoplasm who achieved complete remission after receiving a single dose of MiNK’s agenT-797 therapy combined with nivolumab. The patient had previously failed multiple treatments, including platinum-based chemotherapy, autologous stem cell transplant, and several immune checkpoint inhibitors. The patient’s response was described as a complete clinical, radiologic, and biochemical remission, with donor iNKT cells remaining detectable for up to six months post-infusion. The treatment was well-tolerated with no cytokine release syndrome or graft-versus-host disease observed.

This case represents the second notable responder to agenT-797 plus anti-PD-1 therapy, following a second-line gastric cancer patient who achieved 42% tumor reduction with more than nine months of progression-free survival after a single infusion. MiNK Therapeutics has reported that survival beyond 12 months has already been observed in several patients in its ongoing Phase 2 trial in second-line gastric cancer, comparing favorably to the 9.6-month median overall survival seen with ramucirumab/paclitaxel in the RAINBOW Phase 3 trial.

MiNK Therapeutics has also secured a grant from the National Institute of Allergy and Infectious Diseases to advance its allo-iNKT cell therapy platform aimed at preventing graft-versus-host disease, a serious condition post-stem cell transplantation. This grant will support collaboration with the University of Wisconsin to enhance the therapy’s development. MiNK is also focusing on other immune technologies, including T cell receptor-based therapies.

While the company is not yet profitable, with an EBITDA of -$9.78M in the last twelve months, InvestingPro reports strong momentum scores and identifies 12 additional key factors that could impact the stock’s future performance.

References:
[1] https://www.investing.com/news/analyst-ratings/mink-therapeutics-stock-maintains-buy-rating-at-hc-wainwright-after-case-study-publication-93CH-4133641